SPOTLIGHT -
Challenges for Following NCCN Guidelines for MET Inhibitors in NSCLC
Martin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.
The Relevance of MET Alterations to Targeted NSCLC Therapies
Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.
